Instituto Rosenbusch S.A (ROSE) Fair Value & Analysis
Healthcare · AR · Market cap 6.8B ARS
Fair value as of: Jun 24, 2026
From 9 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 270.36 ARS to 104.10 ARS (−61.5%) since Jun 23, 2026.
Price vs Fair Value (12 months)
12‑month range 119.50 ARS – 327.00 ARS · fair‑value band 67.67 ARS – 140.53 ARS · the 163.00 ARS price screens above the 104.10 ARS fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Instituto Rosenbusch S.A (ROSE) currently trades at 163.00 ARS, while our model-based Fair Value estimate is 104.10 ARS — implying the stock looks roughly 36.1% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Instituto Rosenbusch S.A generated revenue of 6.4B ARS at a net margin of -71.8%. Revenue declined 10.5% year over year. Net debt stands at 738M ARS. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals. The company was founded in 1917 and is based in Buenos Aires, Argentina.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Instituto Rosenbusch S.A reported revenue of 6.4B ARS in FY2025 versus 782M ARS in FY2021, a compound +69.2%/yr. Reported net income was −4.6B ARS in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Instituto Rosenbusch S.A (ROSE) undervalued?
What is the fair value of ROSE?
What is the quality score of ROSE?
What is the revenue of Instituto Rosenbusch S.A (ROSE)?
What is the net profit margin of ROSE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.